BioPhausia, Medivir deal

Medivir will acquire specialty pharma BioPhausia in a cash and stock deal that values BioPhausia at SEK1.65 per share, or about SEK565 million ($91 million). The price is a 45% premium to BioPhausia's close of SEK1.14 on April 8, before the deal was announced. Medivir said the acquisition will expand its commercial activities in the Nordic region in advance of the potential launch of HCV candidate TMC435. The HCV NS3/4A protease inhibitor is in Phase III testing. The Tibotec Pharmaceuticals Ltd. unit of Johnson & Johnson (NYSE:JNJ, New Brunswick, N.J.) has ex-Nordic rights to develop and commercialize TMC435 from Medivir. ...